Drugs / Yeztugo
Yeztugo cost
lenacapavir · Gilead. Every official price for Yeztugo, side by side, with who pays it.
Short answer
FDA approved Yeztugo (lenacapavir) on Jun 18, 2025. We found no list price (wholesale acquisition cost) for Yeztugo on Gilead's own pages, so we do not show one. Medicare Part B pays up to $16.016 per mg for Yeztugo injection for HIV PrEP and $617.946 per 300 mg for Yeztugo tablet for HIV PrEP (October 1, 2026 to December 31, 2026).31
Source: FDA and CMS · checked Nov 7, 2026
Yeztugo: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price | Not published | We found no list price (wholesale acquisition cost) for Yeztugo on Gilead's own pages, so we do not show one. | — |
| Medicare Part B payment limit per mg, Yeztugo injection for HIV PrEP | $16.0161 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 0%. | October 1, 2026 – December 31, 2026 |
| Medicare Part B payment limit per 300 mg, Yeztugo tablet for HIV PrEP | $617.9461 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 0%. | October 1, 2026 – December 31, 2026 |
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Approved by the FDA on Jun 18, 2025 as a new drug (lenacapavir).3
- FDA label, in FDA's words: "YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition."4 The current label may list more uses; ask your doctor or pharmacist what applies to you.
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | Not published | We found no list price (wholesale acquisition cost) for Yeztugo on Gilead's own pages, so we do not show one. | — |
| Medicare Part B payment limit Yeztugo injection for HIV PrEP (lenacapavir) · HCPCS J0738 | $16.0161 | Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 0%. | October 1, 2026 – December 31, 2026 |
| Medicare Part B payment limit Yeztugo tablet for HIV PrEP (lenacapavir) · HCPCS J0752 | $617.9461 | Per 300 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 0%. | October 1, 2026 – December 31, 2026 |
| Pharmacy acquisition cost (NADAC) | Not listed | This drug is not in the NADAC survey, which covers drugs dispensed by retail pharmacies. | — |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.2
With Medicare
- When given in a clinic and paid under Medicare Part B, Medicare's payment is based on the limit above, and CMS lists the coinsurance as 0%.1 A Medicare Supplement (Medigap) policy or Medicare Advantage plan changes what you pay.
- CMS, Medicare coverage of PrEP: "Medicare now covers Yeztugo (lenacapavir) for Pre-exposure Prophylaxis (PrEP)."5
- CMS, National Coverage Determination 210.15 (HIV PrEP): "Effective for claims with dates of service on or after September 30, 2024, CMS covers PrEP using antiretroviral drugs approved by the U.S. Food and Drug Administration (FDA) to prevent HIV in individuals at increased risk of HIV acquisition."6
- Higher income? Part B and Part D premiums can include IRMAA: IRMAA brackets.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Gilead: YEZTUGO cost and coverage. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (6)
- CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026
“The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026“NDA220018 ORIG-1 approved 20250618”
FDA (Drugs@FDA via openFDA): NDA220018 · as of Nov 7, 2026“YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition.”
FDA label for Yeztugo (via openFDA) · as of Oct 25, 2026“Medicare now covers Yeztugo (lenacapavir) for Pre-exposure Prophylaxis (PrEP).”
CMS: Medicare coverage of PrEP · as of Oct 25, 2026“Effective for claims with dates of service on or after September 30, 2024, CMS covers PrEP using antiretroviral drugs approved by the U.S. Food and Drug Administration (FDA) to prevent HIV in individuals at increased risk of HIV acquisition.”
CMS: National Coverage Determination 210.15 (HIV PrEP) · as of Oct 25, 2026